See more : Arion banki hf. (ARION-SDB.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Cumberland Pharmaceuticals Inc. (CPIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cumberland Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Liverpool Group, Inc. (LVRP) Income Statement Analysis – Financial Results
- PT Medco Energi Internasional Tbk (MEDC.JK) Income Statement Analysis – Financial Results
- Recovery International Co.,Ltd. (9214.T) Income Statement Analysis – Financial Results
- RenaissanceRe Holdings Ltd. (RNR-PE) Income Statement Analysis – Financial Results
- Japan Airport Terminal Co., Ltd. (JTTRY) Income Statement Analysis – Financial Results
Cumberland Pharmaceuticals Inc. (CPIX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cumberlandpharma.com
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.55M | 42.01M | 35.99M | 37.44M | 34.39M | 40.74M | 41.15M | 33.03M | 33.52M | 36.90M | 32.03M | 48.85M | 51.14M | 45.88M | 43.54M | 35.08M | 28.06M | 17.82M | 10.69M |
| Cost of Revenue | 6.07M | 9.12M | 8.81M | 8.65M | 7.42M | 7.38M | 7.37M | 5.96M | 4.97M | 5.05M | 5.44M | 5.05M | 5.36M | 3.59M | 4.14M | 3.05M | 2.67M | 2.40M | 533.26K |
| Gross Profit | 33.49M | 32.89M | 27.17M | 28.79M | 26.97M | 33.36M | 33.78M | 27.07M | 28.55M | 31.85M | 26.59M | 43.81M | 45.78M | 42.29M | 39.40M | 32.03M | 25.39M | 15.42M | 10.16M |
| Gross Profit Ratio | 84.66% | 78.29% | 75.51% | 76.89% | 78.42% | 81.89% | 82.09% | 81.96% | 85.18% | 86.31% | 83.02% | 89.67% | 89.51% | 92.18% | 90.50% | 91.32% | 90.49% | 86.53% | 95.01% |
| Research & Development | 5.83M | 6.69M | 5.68M | 5.77M | 6.87M | 7.32M | 3.90M | 3.19M | 3.85M | 3.39M | 5.62M | 5.10M | 5.03M | 4.33M | 4.99M | 4.43M | 3.69M | 2.23M | 1.16M |
| General & Administrative | 10.65M | 10.18M | 9.78M | 10.20M | 9.97M | 10.41M | 10.03M | 8.56M | 7.61M | 8.40M | 9.49M | 9.10M | 9.20M | 7.99M | 7.64M | 5.14M | 4.14M | 3.00M | 2.59M |
| Selling & Marketing | 18.45M | 16.66M | 15.02M | 14.77M | 15.28M | 20.26M | 21.49M | 14.55M | 13.99M | 14.90M | 14.39M | 20.33M | 20.94M | 22.67M | 20.19M | 14.39M | 10.05M | 7.35M | 5.65M |
| SG&A | 29.10M | 26.84M | 24.80M | 24.96M | 25.25M | 30.66M | 31.52M | 23.12M | 21.60M | 23.30M | 23.88M | 29.43M | 30.14M | 30.66M | 27.84M | 19.53M | 14.19M | 10.35M | 8.24M |
| Other Expenses | 8.10M | 5.07M | 4.37M | 4.43M | 4.13M | 2.77M | 2.44M | 2.19M | 1.99M | 1.60M | 896.16K | 466.13K | 655.30K | 686.91K | 793.68K | 791.11K | 783.43K | 611.61K | 13.49K |
| Operating Expenses | 39.39M | 38.60M | 34.85M | 35.17M | 36.26M | 40.75M | 37.86M | 28.50M | 27.44M | 28.29M | 30.39M | 34.99M | 35.93M | 35.79M | 33.62M | 24.75M | 18.67M | 13.19M | 9.41M |
| Cost & Expenses | 45.46M | 47.72M | 43.66M | 43.82M | 43.68M | 48.13M | 45.23M | 34.46M | 32.41M | 33.34M | 35.83M | 40.03M | 41.29M | 39.37M | 37.76M | 27.79M | 21.34M | 15.59M | 9.94M |
| Interest Income | 286.85K | 98.41K | 26.08K | 75.35K | 243.36K | 564.48K | 299.33K | 204.66K | 209.18K | 251.45K | 230.29K | 304.87K | 210.73K | 200.21K | 79.36K | 241.28K | 382.92K | 208.68K | 89.24K |
| Interest Expense | 667.86K | 586.00K | 98.03K | 263.63K | 246.19K | 195.85K | 92.90K | 106.39K | 73.86K | 67.07K | 103.42K | 71.99K | 353.50K | 1.42M | 772.93K | 213.30K | 639.59K | 721.80K | 63.20K |
| Depreciation & Amortization | 5.77M | 5.33M | 4.61M | 4.75M | 4.40M | 2.98M | 2.65M | 2.40M | 2.25M | 1.99M | 1.30M | 901.65K | 1.04M | 978.40K | 816.50K | 786.60K | 762.22K | 587.74K | 53.54K |
| EBITDA | 153.32K | 332.92K | -857.83K | -1.56M | -4.64M | -8.19M | -1.13M | 1.17M | 3.57M | 5.73M | -2.27M | 10.02M | 11.00M | 7.68M | 6.67M | 8.31M | 7.87M | 3.02M | 882.39K |
| EBITDA Ratio | 0.39% | -0.66% | -2.38% | -4.16% | -13.49% | -9.43% | -2.76% | 3.54% | 10.64% | 15.72% | -7.09% | 20.52% | 21.71% | 16.74% | 15.33% | 23.69% | 28.05% | 16.92% | 8.25% |
| Operating Income | -6.21M | -5.70M | -7.68M | -6.38M | -9.29M | -7.39M | -4.08M | -1.43M | -1.11M | 3.56M | -3.80M | 8.82M | 9.85M | 6.50M | 5.78M | 7.28M | 6.73M | 2.22M | 749.92K |
| Operating Income Ratio | -15.70% | -13.58% | -21.34% | -17.04% | -27.01% | -18.14% | -9.92% | -4.34% | -3.32% | 9.64% | -11.87% | 18.05% | 19.26% | 14.17% | 13.27% | 20.76% | 23.96% | 12.48% | 7.02% |
| Total Other Income/Expenses | -74.18K | 123.74K | 2.12M | -188.28K | -2.82K | 368.64K | 206.42K | 98.27K | 135.33K | 184.37K | 126.87K | 232.88K | -142.77K | -1.22M | -693.56K | 27.98K | -256.67K | -515.93K | 20.40K |
| Income Before Tax | -6.28M | -5.58M | -5.56M | -6.57M | -9.29M | -7.02M | -3.87M | -1.33M | 1.25M | 3.74M | -3.67M | 9.05M | 9.71M | 5.28M | 5.08M | 7.31M | 6.47M | 1.71M | 770.32K |
| Income Before Tax Ratio | -15.89% | -13.29% | -15.46% | -17.55% | -27.02% | -17.24% | -9.42% | -4.04% | 3.72% | 10.14% | -11.47% | 18.53% | 18.98% | 11.51% | 11.68% | 20.84% | 23.05% | 9.59% | 7.21% |
| Income Tax Expense | 45.77K | 68.85K | 34.89K | 55.90K | -79.32K | 16.64K | 4.17M | -330.92K | 575.83K | 1.38M | -1.52M | 3.24M | 4.08M | 2.85M | 2.02M | 2.54M | 2.42M | -2.70M | -1.18M |
| Net Income | -6.28M | -5.65M | -5.60M | -6.63M | -9.21M | -6.96M | -7.98M | -944.68K | 731.35K | 2.42M | -2.10M | 5.84M | 5.66M | 2.46M | 3.09M | 4.77M | 4.04M | 4.40M | 1.95M |
| Net Income Ratio | -15.88% | -13.45% | -15.55% | -17.70% | -26.79% | -17.09% | -19.39% | -2.86% | 2.18% | 6.57% | -6.57% | 11.96% | 11.06% | 5.36% | 7.10% | 13.59% | 14.41% | 24.72% | 18.28% |
| EPS | -0.44 | -0.39 | -0.38 | -0.44 | -0.60 | -0.45 | -0.50 | -0.06 | 0.04 | 0.14 | -0.11 | 0.30 | 0.28 | 0.12 | 0.22 | 0.47 | 0.40 | 0.45 | 0.21 |
| EPS Diluted | -0.44 | -0.39 | -0.38 | -0.44 | -0.60 | -0.45 | -0.50 | -0.06 | 0.04 | 0.14 | -0.11 | 0.30 | 0.28 | 0.12 | 0.17 | 0.29 | 0.24 | 0.27 | 0.12 |
| Weighted Avg Shares Out | 14.30M | 14.56M | 14.90M | 15.16M | 15.40M | 15.57M | 15.91M | 15.74M | 16.72M | 17.62M | 18.33M | 19.56M | 20.34M | 20.33M | 14.20M | 10.14M | 10.03M | 9.80M | 9.50M |
| Weighted Avg Shares Out (Dil) | 14.30M | 14.56M | 14.90M | 15.16M | 15.40M | 15.61M | 15.91M | 16.24M | 17.09M | 17.90M | 18.33M | 19.79M | 20.57M | 21.06M | 18.23M | 16.54M | 16.58M | 16.45M | 16.09M |
10 Penny Stocks To Buy In December According To Insiders
Cumberland Pharmaceuticals Stock (CPIX): Why The Price Surged Today
5 Penny Stocks To Buy In December According To Insiders
Penny Stocks To Buy This Week: 4 To Watch Right Now
List of Penny Stocks to Watch While The Stock Market is Down Today
OLMA Stock: The Breast Cancer Therapy News That Has Olema Pharmaceuticals Plunging Today
Read Why Shares Of Nano Cap Cumberland Pharma More Than Doubled
Cumberland Pharmaceuticals (CPIX) Stock: Why The Price Surged Today
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q3 2021 Results - Earnings Call Transcript
Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis
Source: https://incomestatements.info
Category: Stock Reports